Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mankind Pharma Limited (MANKIND.NS)
New Delhi, IN
Mankind Pharma Limited specializes in the development, manufacturing, and marketing of a broad range of pharmaceutical medications and consumer health goods. Operating predominantly in India, the company also caters to international markets. Its pharmaceutical division focuses on both acute and chronic therapeutic areas, encompassing a wide spectrum of medical conditions such as infectious diseases, cardiovascular ailments, gastrointestinal disorders, diabetes, dermatology, pain management, neuro/CNS issues, nutritional support (vitamins/minerals), and respiratory problems. Complementing its pharmaceutical portfolio, the consumer healthcare segment offers diverse products, including condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. Key brands under its umbrella include Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar. Furthermore, the company's business activities are diversified, extending to the trading and export of pharmaceutical and healthcare products, as well as the manufacturing of various goods such as packaging materials, ayurvedic products, bulk drugs, and general consumer items. Mankind Pharma also holds interests in real estate, leasing, hospitality, and IT services. Established in 1986, Mankind Pharma Limited maintains its headquarters in New Delhi, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.33% | -4.83% | +2.76% | +3.23% | +4.05% | +5.63% | -3.90% | +66.27% | +63.13% | +63.13% | +63.13% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 8 | 0 |
| Buy | 7 | -1 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 3 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+17.0% ★ Q1'26: +14.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-5.7% Q1'26: +30.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+14.5% Q1'26: +39.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+19.1% ★ Q1'26: +20.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.9% ★ Q1'26: +11.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.1% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.74× Q1'26: 1.70× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 16 Rev. Ana. 12 EPS Ana. |
Mar 2027 17 Rev. Ana. 15 EPS Ana. |
Mar 2028 19 Rev. Ana. 16 EPS Ana. |
Mar 2029 6 Rev. Ana. 5 EPS Ana. |
Mar 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
87.49B
est: 87.78B (-0.3%)
|
102.59B
est: 106.50B (-3.7%)
|
122.07B
est: 123.18B (-0.9%)
|
142.69B
141.13B – 144.19B
+15.8% YoY
|
159.63B
157.10B – 164.54B
+11.9% YoY
|
177.67B
154.69B – 192.01B
+11.3% YoY
|
197.42B
197.38B – 197.45B
+11.1% YoY
|
199.27B
184.20B – 210.64B
+0.9% YoY
|
| EBITDA |
20.37B
est: 23.16B (-12.0%)
|
28.04B
est: 28.40B (-1.3%)
|
35.58B
est: 32.85B (+8.3%)
|
38.05B
37.64B – 38.45B
+15.8% YoY
|
42.57B
41.89B – 43.88B
+11.9% YoY
|
47.38B
41.25B – 51.20B
+11.3% YoY
|
52.65B
52.64B – 52.66B
+11.1% YoY
|
53.14B
49.12B – 56.17B
+0.9% YoY
|
| EBIT |
17.12B
est: 20.22B (-15.4%)
|
24.26B
est: 23.96B (+1.2%)
|
29.37B
est: 27.71B (+6.0%)
|
32.10B
31.75B – 32.44B
+15.8% YoY
|
35.91B
35.34B – 37.02B
+11.9% YoY
|
39.97B
34.80B – 43.20B
+11.3% YoY
|
44.41B
44.41B – 44.42B
+11.1% YoY
|
44.83B
41.44B – 47.39B
+0.9% YoY
|
| Net Income |
12.82B
est: 13.26B (-3.3%)
|
19.13B
est: 19.63B (-2.5%)
|
19.91B
est: 18.93B (+5.2%)
|
19.13B
17.08B – 20.07B
+1.1% YoY
|
23.68B
21.53B – 26.15B
+23.8% YoY
|
29.77B
24.92B – 34.61B
+25.7% YoY
|
33.91B
32.54B – 39.54B
+13.9% YoY
|
43.63B
39.34B – 46.87B
+28.7% YoY
|
| SGA |
23.13B
est: 17.53B (+31.9%)
|
28.83B
est: 28.51B (+1.1%)
|
34.73B
est: 32.98B (+5.3%)
|
38.20B
37.79B – 38.61B
+15.8% YoY
|
42.74B
42.06B – 44.05B
+11.9% YoY
|
47.57B
41.42B – 51.41B
+11.3% YoY
|
52.86B
52.85B – 52.87B
+11.1% YoY
|
53.35B
49.32B – 56.40B
+0.9% YoY
|
| EPS |
32.00
est: 32.77 (-2.3%)
|
47.75
est: 48.99 (-2.5%)
|
49.17
est: 48.83 (+0.7%)
|
45.58
41.31 – 48.56
-6.7% YoY
|
57.87
52.09 – 63.27
+27.0% YoY
|
70.78
60.28 – 83.72
+22.3% YoY
|
87.48
78.72 – 95.66
+23.6% YoY
|
105.56
95.18 – 113.39
+20.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-01 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree True Emerging Markets Fund XC | 0.07% | 59.4K | 0.32% |
| 2 | WisdomTree India Earnings Fund EPI | 0.05% | 1.05M | 0.84% |
| 3 | WisdomTree Emerging Markets ex-State-Owned Enterprises UCITS ETF - USD Acc XSOE.L | 0.04% | 9.8K | 0.32% |
| 4 | WisdomTree Emerging Markets ex-State-Owned Enterprises Fund XSOE | 0.03% | 728.3K | 0.32% |
| 5 | Schwab Emerging Markets Equity ETF SCHE | 0.03% | 3.56M | 0.06% |
| 6 | State Street SPDR MSCI Emerging Markets Fossil Fuel Reserves Free ETF EEMX | 0.02% | 41.4K | 0.30% |
| 7 | State Street SPDR MSCI Emerging Markets StrategicFactors ETF QEMM | 0.01% | 3.1K | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rajeev Juneja | Vice Chairman & MD | 287M | male |
| Ramesh C. Juneja | Whole-Time Director & Executive Chairman | 259M | male |
| Sheetal Arora | Chief Executive Officer & Whole-Time Director | 152M | male |
| Satish Kumar Sharma | Whole-Time Director | 11M | male |
| Chanakya Juneja | Director of Technology | — | male |
| Abhishek Agarwal | Head of Investor Relations | — | male |
| Prem Kumar Arora | Director of Finance, Human Resources & Admin | — | male |
| Pramod Gokhale | Senior President & Group Chief Information Officer | — | male |
| Anil Kumar | Chief Scientific Officer (Research Centre) | — | — |
| Arjun Juneja | Chief Operating Officer | — | male |
| Ashutosh Dhawan | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MANKIND.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
